Aug. 3 at 5:40 PM
$IBRX Indeed this needs a shot in the arm, or better a drip of anktiva in order to boost its immune response to negativity in the market from shorters and bad actors ;-) 7.5bn valuation for a bio tech with global approvals, growing revenue, breakeven late 2026/early 2027, upcoming approvals for lung, lymphopenia, its own iBCG, IP in NK, robotics, AI, its own manufacturing facility in development, partnerships for africa, no ATMs or placements coming up, etc
Sometimes it is easy to forget how diverse this portfolio has become when the SP gets knocked around. It will come good.
